Noninvasive prenatal screening (NIPS) using cell-free DNA has transformed prenatal care. Belgium was the first country to implement and fully reimburse NIPS as a first-tier screening test offered to all pregnant women. A consortium consisting of all Belgian genetic centers report the outcome of two years genome-wide NIPS implementation.
The performance for the common trisomies and for secondary findings was evaluated based on 153,575 genome-wide NIP tests. Furthermore, the evolution of the number of invasive tests and the incidence of Down syndrome live births was registered.
Trisomies 21, 18, and 13 were detected in respectively 0.32%, 0.07%, and 0.06% of cases, with overall positive predictive values (PPVs) of 92.4%, 84.6%, and 43.9%. Rare autosomal trisomies and fetal segmental imbalances were detected in respectively 0.23% and 0.07% of cases with PPVs of 4.1% and 47%. The number of invasive obstetric procedures decreased by 52%. The number of trisomy 21 live births dropped to 0.04%.
Expanding the scope of NIPS beyond trisomy 21 fetal screening allows the implementation of personalized genomic medicine for the obstetric population. This genome-wide NIPS approach has been embedded successfully in prenatal genetic care in Belgium and might serve as a framework for other countries offering NIPS.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
This clinical utility study presents aggregated clinical data. All data are presented within the paper.
Vermeesch, J. R., Voet, T. & Devriendt, K. Prenatal and pre-implantation genetic diagnosis. Nat. Rev. Genet. 17, 643–656 (2016).
Fan, H. C., Blumenfeld, Y. J., Chitkara, U., Hudgins, L. & Quake, S. R. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc. Natl. Acad. Sci. U. S. A. 105, 16266–16271 (2008).
Chiu, R. W. K. et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc. Natl. Acad. Sci. U. S. A. 105, 20458–20463 (2008).
Gil, M. M., Accurti, V., Santacruz, B., Plana, M. N. & Nicolaides, K. H. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet. Gynecol. 50, 302–314 (2017).
Taylor-Phillips, S. et al. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ Open 6, e010002 (2016).
Badeau, M. et al. Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women. Cochrane Database Syst. Rev. 11, CD011767 (2017).
Gregg, A. R. et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet. Med. 18, 1056–1065 (2016).
Committee opinion no. 640: cell-free DNA screening for fetal aneuploidy. Obstet. Gynecol. 126, e31–e37 (2015).
Society for Maternal-Fetal Medicine (SMFM) Publications Committee. SMFM statement: clarification of recommendations regarding cell-free DNA aneuploidy screening. Am. J. Obstet. Gynecol. 213, 753–754 (2015).
Benn, P. et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat. Diagn. 35, 725–734 (2015).
Bianchi, D. W. & Chiu, R. W. K. Sequencing of circulating cell-free DNA during pregnancy. N. Engl. J. Med. 379, 464–473 (2018).
Gadsbøll, K. et al. Current use of noninvasive prenatal testing in Europe, Australia and the USA: a graphical presentation. Acta Obstet. Gynecol. Scand. 99, 722–730 (2020).
Van Elslande, J. et al. The sudden death of the combined first trimester aneuploidy screening, a single centre experience in Belgium. Clin. Chem. Lab. Med. 57, e294–e297 (2019).
FPS Public Health. Opinion no. 66 of 9 May 2016—non-invasive prenatal testing (NIPT). https://www.health.belgium.be/en/opinion-no-66-non-invasive-prenatal-testing-nipt (2016).
Belgium Society of Human Genetics prenatal working group. Belgian Guidlines for managing incidental findings detected by NIPT. https://www.college-genetics.be/assets/recommendations/fr/guidelines/BELGIAN%20GUIDELINES%20FOR%20MANAGING%20INCIDENTAL%20FINDINGS%20DETECTED%20BY%20NIPT%20(2019).pdf.
Kalia, S. S. et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet. Med. 19, 249–255 (2017).
Bayindir, B. et al. Noninvasive prenatal testing using a novel analysis pipeline to screen for all autosomal fetal aneuploidies improves pregnancy management. Eur. J. Hum. Genet. 23, 1286–1293 (2015).
Dheedene, A. et al. Implementation of non-invasive prenatal testing by semiconductor sequencing in a genetic laboratory. Prenat. Diagn. 36, 699–707 (2016).
Raman, L., Dheedene, A., De Smet, M., Van Dorpe, J. & Menten, B. WisecondorX: improved copy number detection for routine shallow whole-genome sequencing. Nucleic Acids Res. 47, 1605–1614 (2019).
Engel, E. A fascination with chromosome rescue in uniparental disomy: Mendelian recessive outlaws and imprinting copyrights infringements. Eur. J. Hum. Genet. 14, 1158–1169 (2006).
Brison, N. et al. Accuracy and clinical value of maternal incidental findings during noninvasive prenatal testing for fetal aneuploidies. Genet. Med. 19, 306–313 (2017).
Ammon Avalos, L., Galindo, C. & Li, D.-K. A systematic review to calculate background miscarriage rates using life table analysis. Birth Defects Res. A Clin. Mol. Teratol. 94, 417–423 (2012).
Gyselaers, W., Hulstaert, F. & Neyt, M. Contingent non-invasive prenatal testing: an opportunity to improve non-genetic aspects of fetal aneuploidy screening. Prenat. Diagn. 35, 1347–1352 (2015).
Yaron, Y. The implications of non-invasive prenatal testing failures: a review of an under-discussed phenomenon. Prenat. Diagn. 36, 391–396 (2016).
van der Meij, K. R. M. et al. TRIDENT-2: national implementation of genome-wide noninvasive prenatal testing as a first-tier screening test in the Netherlands. Am. J. Hum. Genet. 105, 1091–1101 (2019).
Pertile, M. D. et al. Rare autosomal trisomies, revealed by maternal plasma DNA sequencing, suggest increased risk of feto-placental disease. Sci. Transl. Med. 9, eaan1240 (2017).
Scott, F. et al. Rare autosomal trisomies: Important and not so rare. Prenat. Diagn. 38, 765–771 (2018).
Brison, N. et al. Predicting fetoplacental chromosomal mosaicism during non-invasive prenatal testing. Prenat. Diagn. 38, 258–266 (2018).
Amant, F. et al. Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing. JAMA Oncol. 1, 814–819 (2015).
Brison, N. et al. Maternal copy-number variations in the DMD gene as secondary findings in noninvasive prenatal screening. Genet. Med. 21, 2774–2780 (2019).
Robson, S. J. & Hui, L. National decline in invasive prenatal diagnostic procedures in association with uptake of combined first trimester and cell-free DNA aneuploidy screening. Aust. N. Z. J. Obstet. Gynaecol. 55, 507–510 (2015).
Larion, S. et al. Association of combined first-trimester screen and noninvasive prenatal testing on diagnostic procedures. Obstet. Gynecol. 123, 1303–1310 (2014).
Platt, L. D. et al. Impact of noninvasive prenatal testing in regionally dispersed medical centers in the United States. Am J Obstet. Gynecol. 211, 368.e1–7 (2014).
van Schendel, R. V. et al. Attitudes of pregnant women and male partners towards non-invasive prenatal testing and widening the scope of prenatal screening. Eur. J. Hum. Genet. 22, 1345–1350 (2014).
Hill, M. et al. Has noninvasive prenatal testing impacted termination of pregnancy and live birth rates of infants with Down syndrome? Prenat. Diagn. 37, 1281–1290 (2017).
Dondorp, W. et al. Noninvasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur. J. Hum. Genet. 23, 1438–1450 (2015).
Grati, F. R. et al. Outcomes in pregnancies with a confined placental mosaicism and implications for prenatal screening using cell-free DNA. Genet. Med. 22, 309–316 (2020).
Malvestiti, F. et al. Interpreting mosaicism in chorionic villi: results of a monocentric series of 1001 mosaics in chorionic villi with follow-up amniocentesis. Prenat. Diagn. 35, 1117–1127 (2015).
Toutain, J., Goutte-Gattat, D., Horovitz, J. & Saura, R. Confined placental mosaicism revisited: impact on pregnancy characteristics and outcome. PLoS One 13, e0195905 (2018).
van Schendel, R. V. et al. What do parents of children with Down syndrome think about non-invasive prenatal testing (NIPT)? J. Genet. Couns. 26, 522–531 (2017).
Crombag, N. M., Page-Christiaens, G. C., Skotko, B. G. & de Graaf, G. Receiving the news of Down syndrome in the era of prenatal testing. Am. J. Med. Genet. A 182, 374–385 (2020).
Part of this work was funded by KULeuven funding (C1/018).
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Van Den Bogaert, K., Lannoo, L., Brison, N. et al. Outcome of publicly funded nationwide first-tier noninvasive prenatal screening. Genet Med (2021). https://doi.org/10.1038/s41436-021-01101-4